- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03826147
Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease
May 15, 2023 updated by: Douglas Seals, University of Colorado, Boulder
Nitric oxide (NO) is an essential molecule in the body that is decreased in patients with chronic kidney disease (CKD), leading to reductions in vascular, movement ("motor") and cognitive functions.
This study will determine if daily oral supplementation (3 months) with a supplement that increases NO in the body, i.e., nitrate-rich beetroot juice, improves vascular, motor and cognitive function in patients with CKD; this study will also provide insight into the biological reasons (mechanisms) by which supplementation with nitrate-rich beetroot juice improves vascular function in these patients.
Overall, this research will provide scientific evidence supporting the use of nitrate-rich beetroot juice for preserving physiological function and preventing co-morbid clinical conditions and disability in CKD.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
92
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hannah Lally
- Phone Number: 303-735-6410
- Email: beetrootstudy@colorado.edu
Study Locations
-
-
Colorado
-
Boulder, Colorado, United States, 80309
- Recruiting
- Integrative Physiology of Aging Laboratory
-
Contact:
- Melanie R Zigler, M.S.
- Phone Number: 303-492-2485
- Email: melanie.connell@colorado.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- CKD stage II-IV (eGFR using the Modification of Diet in Renal Disease (MDRD) prediction equation 20-90 mL/min/1.73m2; stable renal function in the past 3 months)
- Ability to give informed consent
- Albumin > 3.0 g/dL
- Ability to perform motor and cognitive tests (e.g., can rise from a chair, walk for 6 min, climb 10 stairs)
- Free from alcohol dependence or abuse, as defined by the American Psychiatry Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-V)
- Mini-mental state examination score >21 (rationale: to screen for subjects with major cognitive impairment)
- Blood pressure (BP) >100/60 mmHg for past 3 months (rationale: blood pressure below 100/60 mmHg may elevate the normally small risk of hypotension with nitrate supplementation)
- Not taking medications that will interfere with administered medications (e.g., sildenafil interacts with nitroglycerin)
- Body mass index (BMI) <40 kg/m2 (vascular function measurements can be inaccurate in severely obese patients)
Exclusion Criteria:
- Life expectancy <1 year
- Uncontrolled hypertension, defined as blood pressure > 160/100 mmHg in the past 3 months
- History of severe liver disease
- History of severe congestive heart failure (i.e., ejection fraction < 35%)
- History of hospitalizations within the last 3 months
- Active infection or antibiotic therapy
- Warfarin use
- Vasculitis requiring immunosuppressive therapy within the last year
- High dietary nitrate intake or current nitrate/nitrite supplementation; hypersensitivity to nitrates or nitrites
- Glucose-6-phosphate dehydrogenase deficiency or blood methemoglobin >2%
- Unwilling to abstain from use of mouthwash or other oral hygiene practices (e.g., tongue scraping) outside of teeth brushing that disrupt the oral microbiome and would interfere with nitrate conversion to nitrite
- Blood donation within 8 weeks prior to enrolling in the study; unwilling to abstain from donating blood for 8 weeks after completing the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nitrate-rich beetroot juice
Daily dose of nitrate-rich beetroot juice (70 mL) for 3 months.
|
Daily supplementation with ~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
|
Placebo Comparator: Nitrate-depleted beetroot juice
Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months.
The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.
|
Daily supplementation with ~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in vascular endothelial function
Time Frame: Baseline, 3 months
|
as measured by brachial artery flow-mediated dilation
|
Baseline, 3 months
|
Change in aortic stiffness
Time Frame: Baseline, 3 months
|
as measured by carotid-femoral pulse wave velocity
|
Baseline, 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in oxidative stress-associated suppression of endothelial function assessed as the increase in brachial artery flow-mediated dilation following an ascorbic acid infusion
Time Frame: Baseline, 3 months
|
The influence of oxidative stress on brachial artery flow-mediated dilation will be determined by infusing a supraphysiological dose of ascorbic acid known to scavenge superoxide or isovolumic saline
|
Baseline, 3 months
|
Change in endothelial cell markers of oxidative stress
Time Frame: Baseline, 3 months
|
Endothelial cell nitrotyrosine levels will be determined
|
Baseline, 3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor function composite score
Time Frame: Baseline, 3 months
|
Multiple domains of motor function (including endurance, strength, dexterity) assessed using the NIH Toolbox Motor Battery (aggregated into one reported value)
|
Baseline, 3 months
|
Fluid cognition composite score
Time Frame: Baseline, 3 months
|
Multiple domains of cognitive function (including executive function, memory, processing speed) assessed using the NIH Toolbox Cognitive Battery (aggregated into one reported value)
|
Baseline, 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Matthew J Rossman, PhD, University of Colorado, Boulder
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2019
Primary Completion (Anticipated)
July 1, 2023
Study Completion (Anticipated)
July 1, 2024
Study Registration Dates
First Submitted
January 28, 2019
First Submitted That Met QC Criteria
January 29, 2019
First Posted (Actual)
February 1, 2019
Study Record Updates
Last Update Posted (Actual)
May 17, 2023
Last Update Submitted That Met QC Criteria
May 15, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-0364
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Nitrate-rich beetroot juice
-
University of FloridaRecruitingCoronary Artery DiseaseUnited States
-
University of ExeterCompletedCognitive Change | Blood Pressure | Functional Capacity | Brain MetabolismUnited Kingdom
-
Bangor UniversityCompleted
-
University of Sao PauloRecruitingCardiovascular Abnormalities | Steroid AbuseBrazil
-
University of ReadingSaudi Cultural BureauCompletedNo Dental Disease | Non-smokingUnited Kingdom
-
Universidad Autonoma de MadridUniversidad Politecnica de Madrid; Camilo Jose Cela UniversityCompletedNitrates | Nutrition | Physical Performance | Sport Physiology | Elite Athletes
-
Queen's UniversityCompletedHeart Failure, Systolic
-
University of Sao PauloRecruitingMotor Activity | Physical Inactivity | Postmenopausal; MenorrhagiaBrazil
-
Maastricht University Medical CenterCompletedHigh Intensity Intermittent Sports PerformanceNetherlands
-
Moira TaylorKing Abdulaziz UniversityNot yet recruitingHealthy | Overweight and Obesity | Older AdultsUnited Kingdom